Skin Cancer Treatment Market is expected to reach US$ 19.53 Billion by 2031

Nonmelanoma Segment Based on Type Fuels Skin Cancer Treatment Market Growth

According to our new research study on “Skin Cancer Treatment Market Forecast to 2031 – Global Analysis – by Type, Therapy, and End User,” the market size is expected to grow from US$ 11.79 billion in 2024 to US$ 19.53 billion by 2031; the market is expected to register a CAGR of 7.57% during 2025–2031. Major factors driving the skin cancer treatment market growth include the shift toward precision and patient-centered therapies.

According to the National Cancer Institute, melanoma cases have risen by ~1.2% annually over the past decade, while basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) cases have surged by 145% and 263%, respectively. These trends are strongly linked to prolonged ultraviolet (UV) exposure and insufficient sun protection, particularly in older populations with cumulative UV damage. Data from Cancer Research UK highlight this pattern, reporting a ~57% increase in melanoma incidence among individuals over 80 and a 7% rise among adults aged 25–49 in 2024. Public health campaigns—such as those by Health Canada and the Public Health Agency of Canada—have also contributed to higher diagnosis rates by encouraging routine skin checks, boosting demand for topical treatments and immunotherapies. In Australia, the Institute of Health and Welfare has reported that skin cancers represent a significant share of all cancer cases, with melanoma rates 10–20 times higher than those seen in Europe in 2024.

Skin Cancer Treatment Market, by Region, 2024(%)

Source: The Insight Partners Analysis

The growing prevalence of skin cancers has accelerated the need for advanced treatment options such as checkpoint inhibitors. With governments in the US, the UK, and elsewhere investing in screening programs, prevention strategies, and research, the global skin cancer treatment market is expanding to address this increasing public health challenge. The emphasis remains on prevention, early detection, and the adoption of innovative therapies to reduce the rising disease burden worldwide.

Rising inclination toward sustainable and single-use gloves is projected to be a key driver shaping skin cancer treatment market trends in the near future.

Skin Cancer Treatment Market Analysis Based on Segmental Evaluation:

Based on type, the market is segmented into Melanoma and Nonmelanoma. The nonmelanoma segment held the largest skin cancer treatment market share in 2024 and is expected to register the highest CAGR during 2025–2031. According to the Skin Cancer Foundation, it is stated that more than 5,400 deaths are reported globally owing to nonmelanoma skin cancer every month. Also, Merkel cell carcinoma has an incidence increased by 95% between 2000 and 2013. However, this type is a rare and aggressive form of skin cancer. Similarly, Europe has a higher risk of UV exposure leading to NMSC, as in this region, ~15 million outdoor workers are exposed to the sun during their working hours without knowing the risks. Malignant melanoma skin cancer is a major cause of death. In addition, this type of cancer is more likely to be reported and accurately diagnosed than nonmelanoma skin cancers. The growing awareness about skin cancer and the availability of advanced diagnosis technologies have enabled to monitor of the increasing number of cases. The awareness about skin cancer has helped increase diagnoses, eventually leading to growth of the market.

By therapy, the skin cancer treatment market is classified into immunotherapy, targeted therapy, chemotherapy, radiation therapy, and others. The immunotherapy segment held a larger share of the skin cancer treatment market in 2024 and is expected to register a higher CAGR during 2025–2031.

In terms of end users, the skin cancer treatment market is segmented into dermatology clinics, hospitals, diagnostic centers, and others. The hospitals segment dominated the skin cancer treatment market in 2024 and is anticipated to register the highest CAGR during 2025–2031.

The scope of the skin cancer treatment market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the skin cancer treatment market share in 2024. The market evolves rapidly owing to rising incidence rates, growing public awareness, and increasing government involvement in cancer prevention and treatment. The CDC identifies skin cancer as the most prevalent cancer in the US, with more than 5 million cases treated annually. Beyond the significant public health toll, it places a heavy economic burden on the healthcare system, costing about US$8.1 billion each year. This makes skin cancer management a priority not just medically, but also economically.

The US Food and Drug Administration (FDA) has also approved several new therapies, including immune checkpoint inhibitors such as pembrolizumab and nivolumab, which continue to reshape treatment strategies for advanced melanoma. In 2024, the FDA also approved lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, for patients with metastatic melanoma who do not respond to the existing treatments, marking a significant advancement in personalized cell-based cancer therapies in North America. Federal and state funding initiatives, such as the Cancer Moonshot initiative, have supported the growing integration of immunotherapies and targeted therapies.

Merck KGaAPfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Amgen Inc, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, GSK Plc, Iovance Biotherapeutics Inc, Genentech Inc. are among the leading companies profiled in the skin cancer treatment market report.

In terms of geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the skin cancer treatment market, primarily due to the high incidence of skin cancer in the US and the increased use of cancer medications in that country. Additionally, major industry players' tendency to develop new skin cancer treatments is expected to influence regional market expansion. Since nonmelanoma skin cancer is more prevalent among Caucasian populations, North America and Europe together represent a significant portion of the global market.

The skin cancer treatment market in Asia Pacific is projected to experience fastest growth during the forecast period, primarily due to the increasing prevalence of both melanoma and nonmelanoma cases in countries such as Australia and New Zealand. The recent regulatory approvals for skin cancer medications and the large, underdeveloped market in many developing countries contribute to the market expansion. Additionally, as melanoma cases continue to rise in Europe, the market revenue in the region is also expected to see healthy development during the forecast period.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com